Palma Bee'Z Research Institute Co., Ltd.
Sanko Junyaku Co., Ltd.
Eisai Co., Ltd.
Palma Bee'Z Research Institute Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Masao Jimbo), Sanko Junyaku Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Masao Jimbo), and Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, President: Haruo Naito) announced today that the three companies concluded a license agreement with OncoTherapy Science, Inc. (OTS, Headquarters: Minato-ku, Tokyo, President: Kensuke Tomita), which approves these three companies to use research information regarding lung cancer gene gained by OTS for their product development of gene diagnostics.
Under this agreement, OTS shall provide information about the specific gene that expresses in lung cancer cells with Palma Bee'Z Research Institute. Based on this target gene information, Palma Bee'Z Research Institute will aim to develop a convenient and highly sensitive novel gene diagnostic kit which is useful for the early diagnosis of lung cancer, evaluation of treatment effectiveness, or prognostic diagnosis by using the PALSAR (Probe Alternation Link Self-Assembly Reaction) method.
OTS is a venture company established to exploit research achievements carried out by Prof. Yusuke Nakamura, the Director of Human Genome Center of the Institute of Medical Science at the University of Tokyo. In cooperation with Prof. Nakamura's group, OTS has conducted total gene expression profile analysis involving cancer.
Palma Bee'Z Research Institute, jointly established by Sanko Junyaku and its parent company, Eisai Co., Ltd., is a R&D company specializing in gene-related technology. Commissioned by the two parent companies, Palma Bee'Z Research Institute has developed R&D for a gene test kit using the novel gene amplification technology called the PALSAR method.
|Sanko Junyaku Co., Ltd.
General Affairs Dept.
|Eisai Co., Ltd.|
Public Relations Dept.